A.G. Kislichko, M.S. Ramazanova, I.F. Nabatov, A.V. Golyakova
Kirov State Medical University, Kirov
Kirov Regional Clinical Oncology Center, Kirov
Kislichko A.G. ― D. Med. Sc., Professor, Head of the oncology department of the Kirov State Medical University
23 Stroiteley Str., Kirov, Russian Federation, 610021, tel. (8332) 52-72-13, e-mail: email@example.com
Abstract. Growth of cancer of colon and rectum depends on intensity of new tumor vessels formation. Angiogenesis triggers a cascade of molecular mechanisms that lead to rapid growth of the tumor. Therefore, it makes sense to use drugs that inhibit the angiogenesis in patients with colorectal cancer. This article presents the results of treatment of 2 groups of patients with metastatic colon cancer, one of which received anti-angiogenic therapy with bevacizumab in addition to standard treatment.
Key words: colorectal cancer, chemotherapy, anti-angiogenic agents.